secwatch / observer
8-K filed October 7, 2025, 7:59 PM ET ticker BURU CIK 0001814215
M&A confidence high sentiment neutral materiality 0.75

Nuburu to acquire Orbit from Executive Chairman for $12.5M; appoints Co-CEOs, faces audit committee non-compliance

Nuburu, Inc.

item 1.01item 5.02item 3.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-25-233623
form_type
8-K
ticker
BURU
cik
0001814215
company_name
Nuburu, Inc.
filed_at
2025-10-07T23:59:59+00:00
discovered_at
2026-05-14T18:02:40.558799+00:00
generated_at
2026-05-17T04:28:45.803290+00:00
sec_items
["1.01", "5.02", "3.01", "9.01"]
event_type
m_and_a
sentiment
neutral
materiality_score
0.75
calibrated_materiality_score
0.75
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-25-233623
json_url
https://secwatch.observer/filing/0001193125-25-233623.json
markdown_url
https://secwatch.observer/filing/0001193125-25-233623.md
text_url
https://secwatch.observer/filing/0001193125-25-233623.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/buru-20251001.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

a2399745486ea98e8a4452c72dc02b714fd0e788

Nuburu, Inc. received a nyse_american noncompliance notice notice regarding audit committee (rules 303A.12(b)).

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

LNAI

Lunai Bioworks completes merger to acquire CNS patent portfolio; issues $20M Series B Preferred Stock

Lunai Bioworks Inc. May 1, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 9.01, 3.01, 3.02, 3.03, 5.03

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 same event type: m_and_a similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S

Filing page SEC filing

STKL

SunOpta completes acquisition by Refresco affiliate for $6.50/share, going private

SunOpta Inc. May 4, 2026, 7:59 PM ET m_and_a Items 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 5.02, 9.01 same event type: m_and_a

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

May 1, 2026, the Company notified the Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Arrangement on May 1, 2026 and requested that Nasdaq halt trading of the Common Shares effective as of 5:00 p.m., Easter

Filing page SEC filing

MDCX

Medicus Pharma closes $22M secured notes with Streeterville; receives Nasdaq MVLS non-compliance notice

Medicus Pharma Ltd. May 27, 2026, 4:45 PM ET debt Items 1.01, 2.03, 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

May 20, 2026, the Company received written notice (the "Notice") from the Listing Qualifications Department of the Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securit

Filing page SEC filing

XHLD

TEN Holdings receives Nasdaq equity deficiency notice; issues 500k shares for $500k

TEN Holdings, Inc. May 26, 2026, 4:05 PM ET regulatory Items 1.01, 3.01, 3.02, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

May 26, 2026, the Company received a deficiency letter from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in compliance with Nasda

Filing page SEC filing

RANI

Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart

Rani Therapeutics Holdings, Inc. May 15, 2026, 4:08 PM ET earnings Items 2.02, 3.01, 5.02, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 5.02, 9.01 similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th

Filing page SEC filing

ISPC

iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance

iSpecimen Inc. May 13, 2026, 5:00 PM ET other_material Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026

Filing page SEC filing

PMI

Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity

Picard Medical, Inc. May 11, 2026, 5:08 PM ET other_material Items 1.01, 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of

Filing page SEC filing

SBEV

Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M

SPLASH BEVERAGE GROUP, INC. May 5, 2026, 7:59 PM ET regulatory Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 similar materiality

This filing

October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th

Comparable filing

April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”) that the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined in Section 1

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-25-233623
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.